All In Biotech

Drug Trial Radar · NCT01254279

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Multicentre, Single-arm, Open Label Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen and to Document Safety of Cabazitaxel in These Patients

Last checked: Nov 19, 2026Latest source record: Jan 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

984

Actual

Start

Dec 2010

Primary completion

Dec 2014

Study completion Dec 2014

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Dec 6, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to allow patients similar to that evaluated in the TROPIC trial (NCT00417079), and Investigators access to cabazitaxel for the management of metastatic Hormone Refractory Prostate Cancer (mHRPC) in those patients who have progressed during or after docetaxel and to document the overall safety of cabazitaxel in these patients. Please note that in each country, patient recruitment will end when cabazitaxel becomes commercially available.

Conditions

  • Prostate Cancer Metastatic

Interventions

  • CABAZITAXELDrug

    Pharmaceutical form: Concentrate For Solution For Infusion Route of administration: Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To provide early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimenTime frame: Up to 30 weeks

Locations

165 sites in 29 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 036004

    Box Hill, Australia

  • Investigational Site Number 036020

    Campbelltown, Australia

  • Investigational Site Number 036001

    Camperdown, Australia

  • Investigational Site Number 036002

    Camperdown, Australia

  • Investigational Site Number 036011

    Douglas, Australia

  • Investigational Site Number 036019

    Nambour, Australia

  • Investigational Site Number 036023

    North Adelaide, Australia

  • Investigational Site Number 036008

    Parkville, Australia

  • Investigational Site Number 036005

    Perth, Australia

  • Investigational Site Number 036003

    Port Macquarie, Australia

  • Investigational Site Number 036025

    Randwick, Australia

  • Investigational Site Number 036009

    South Brisbane, Australia

  • Investigational Site Number 036022

    South Brisbane, Australia

  • Investigational Site Number 036017

    Southport, Australia

  • Investigational Site Number 036012

    St Leonards, Australia

  • Investigational Site Number 036010

    Sydney, Australia

  • Investigational Site Number 036013

    Sydney, Australia

  • Investigational Site Number 036014

    Sydney, Australia

  • Investigational Site Number 036016

    Tweed Heads, Australia

  • Investigational Site Number 036024

    Wendouree, Australia

  • Investigational Site Number 036007

    Westmead, Australia

  • Investigational Site Number 036015

    Wodonga, Australia

  • Investigational Site Number 040-004

    Linz, Austria

  • Investigational Site Number 040-005

    Salzburg, Austria

  • Investigational Site Number 040-002

    Vienna, Austria

  • Investigational Site Number 040-003

    Vienna, Austria

  • Investigational Site Number 056002

    Bruges, Belgium

  • Investigational Site Number 056007

    Brussels, Belgium

  • Investigational Site Number 056003

    Haine-Saint-Paul, Belgium

  • Investigational Site Number 056005

    Liège, Belgium

  • Investigational Site Number 056004

    Ottignies, Belgium

  • Investigational Site Number 056001

    Roeselare, Belgium

  • Investigational Site Number 056006

    Tournai, Belgium

  • Investigational Site Number 070003

    Banja Luka, Bosnia and Herzegovina

  • Investigational Site Number 070001

    Sarajevo, Bosnia and Herzegovina

  • Investigational Site Number 070002

    Zenica, Bosnia and Herzegovina

  • Investigational Site Number 100004

    Plovdiv, Bulgaria

  • Investigational Site Number 100001

    Sofia, Bulgaria

  • Investigational Site Number 100003

    Sofia, Bulgaria

  • Investigational Site Number 100002

    Sofia, Bulgaria

Showing 40 of 165 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.